1. Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.Am J Cardiol. 2006;98:102-106.
2. Adorisio R, De Luca L, Rossi J, Gheorghiade M. Pharmacological treatment of chronic heart failure. Heart Fail Rev. 2006 ;11:109-123.
3. Ahmed A, Fleg JL, Gheorghiade M. Heart failure with preserved ejection fraction. N Engl J Med. 2006 ;355:1829-1830
4. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, Adams KF Jr, Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114:397-403.
5. Ahmed A, Husain A, Love TE, Gambassi G, Dell'Italia LJ, Francis GS,Gheorghiade M, Allman RM, Meleth S, Bourge RC. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006;27:1431-1439.
6. Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS, Adams KF, Gheorghiade M. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post-hoc analysis of the DIG Trial. Eur Heart J 2006; 27: 178-186.
7. Aistrup GL, Kelly J, Piano MR, Wasserstrom JA. Biphasic changes in cardiac excitation-contraction coupling early in chronic alcohol exposure. Amer J Physiol 2006;291:H1047-H1057.
8. Aistrup GL, Kelly JE, Kapur S, Kowalczyk M, Sysman-Wolpin I, Kadish AH, Wasserstrom JA. Pacing-induced heterogeneities in intracellular Ca2+ signaling, cardiac alternans, and ventricular arrhythmias in intact rat heart. Circ Res 2006;99:e65-73.
9. Allen LA, O’Donnell CJ, Giugliano RP, Camargo CA, Lloyd-Jones DM. Comparison of long-term mortality across the spectrum of acute coronary syndromes. Am Heart J 2006; 151: 1072-1078.
10. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, Chae CU, Januzzi JL. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency department (PRIDE) Study. J Amer Coll Cardiol 2006: 47: 91-97.
11. Ardehali H. Signaling mechanisms in ischemic preconditioning: Interaction of PKCe and MitoKATP in the inner membrane of mitochondria. Circ Res 2006;99:798-800.
12. Asai J, Takenaka H, Kusano KK, Ii M, Luedemann C, Curry C, Eaton E, Iwakura A, Tsutsumi Y, Hamada H, Kim MK, Iwakura A, Ii M, Thorne T, Qin G, Asai J, Tsutsumi Y, Sekiguchi H, Silver M, Wecker A, Bord E, Zhu Y, Kishore R, Losordo DW: Estrogen receptors alpha and beta mediate contribution of bone marrow-derived endothelial progenitor cells to functional recovery after myocardial infarction. Circulation 2006;114:2261-2270.
13. Bax JJ, Bonow RO, Tsöchpe D, Inzucchi SE, Barrett E. The potential of myocardial perfusion imaging to identify silent myocardial ischemia in patients with type 2 diabetes. J Am Coll Cardiol 2006;48:754-760
14. Becker CR, Davidson CJ, Lameire N, McCullough PA, Stacul F, Tumlin J, Adam A. High-risk situations and procedures. Am J Cardiol 2006;98(suppl):37K-41K.
15. Beohar N, Robbins JD. Cavanaugh BJ. Ansari AH. Yaghmai V. Carr J. Davidson CJ. Quantitative assessment of in-stent dimensions: a comparison of 64 and 16 detector multislice computed tomography to intravascular ultrasound. Cathet Cardiovasc Intervent. 2006;68:8-10.
16. Beller GA, Bonow RO, Fuster V. ACCF 2006 update for training in adult cardiovascular medicine: Focused update of the 2002 COCATS 2 training statement. J Am Coll Cardiol 2006;47:894-897
17. Bonow RO, Carabello B, Chatterjee K, De Leon AC, Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise J. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease. J Am Coll Cardiol 2006;48:e1-e148 and Circulation 2006;114:e84-e231
18. Bonow RO, Carabello B, Chatterjee K, De Leon AC, Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise J. ACC/AHA 2006 Guidelines for the Management of Patients with Valvular Heart Disease. Executive Summary. J Am Coll Cardiol 2006;48:589-675 and Circulation 2006;114:450-527
19. Bowers, M, Ardehali H. TOM20 and the Heartbreakers: evidence for the role of mitochondrial transport proteins in cardioprotection. J Mol Cell Card 2006;41:406-409.
20. Bucciarelli-Ducci C, Wu E, Lee DC, Holly TA, Klocke FJ, Bonow RO. Contrast-enhanced cardiac magnetic resonance in the evaluation of myocardial infarction and myocardial viability in patients with ischemic heart disease. Curr Probl Cardiol 2006;31:125-168
21. Caira FC, Stock SR, Gleason T, McGee EC, Bonow RO, Spelsberg TC, McCarthy PC, Rahimtoola SH, MB, Rajamannan NM. Human degenerative valve disease is associated with upregulation of Lrp5 receptor mediated bone formation. J Am Coll Cardiol 2006;47:1707-1212
22. Calvin JE, Roe MT, Chen AY, Mehta RH, Brogan GX Jr, Delong ER, Fintel DJ, Gibler WB, Ohman EM, Smith SC Jr, Peterson ED. Insurance coverage and care of patient with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 2006;145:739-748.
23. Carnethon MR, Lynch E, Dyer AR, Lloyd-Jones DM, Wang R, Garside DB, Greenland P. Comparison of risk factors for cardiovascular mortality between black and white adults. Arch Intern Med 2006; 166: 1196-1202.
24. Crowe ME, Rocha CA, Wu E, Carr JC. Complications following the Ross procedure: Cardiac MRI findings. J Thorac Imaging 2006; 21: 213-218.
25. Daimon, M, Fukoda S, Adams, DH, McCarthy, PM, Gillinov AM, Carpentier A, Filsoufi F, Abascal V, Rigolin VH, Salzberg S, Huskin A, Langenfeld M, Shiota T. Mitral valve repair with Carpentier-McCarthy-Adams IMR ETlogix annuloplasty ring for ischemic mitral regurgitation: early echocardiographic results from a multi-center study . Circulation 2006:114:I-588-I-593.
26. Davidson CJ, Stacul F, McCullough PA, Tumlin J, Adam A, Lameire N, Becker CR. Contrast medium use. Am J Cardiol 2006; 98(suppl): 42K-58K.
27. Daviglus ML, Lloyd-Jones DM, Pirzada A. Preventing cardiovascular disease in the 21st century: therapeutic and preventive implications of current evidence. Am J Cardiovasc Drugs 2006; 6: 87-101.
28. De Luca L, Abraham WT, Fonarow GC, Gheorghiade M. Congestion in acute heart failure syndromes: importance of early recognition and treatment.Rev Cardiovasc Med. 2006;7:69-74.
29. De Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M. Evidence-based use of levosimendan in different clinical settings Eur Heart J. 2006;27:1908-1920.
30. Echols MR, Felker GM, Thomas KL, Pieper KS, Garg J, Cuffe MS, Gheorghiade M, Califf RM, O'Connor CM. Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial.J Card Fail 2006;12:684-688.
31. Ellenbogen KA, Levine JH, Berger RD, Daubert JP, Winters SL, Greenstein E, Schaecter A, Subacius H, Kadish A. Are implanable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation 2006.;113:776-782.
32. Endres S, Mayuga KA, de Cristofaro A, Taneja T, Goldberger JJ, Kadish AH. Age and gender difference in ST height at rest and after double autonomic blockade in normal adults. Ann Noninvasive Electrocardiol. 2006;11:253-258.
33. Gheorghiade M, Sopko, G, De Luca L, Velazquez EJ, Parker JD, Binkley PF, Sadowski Z, Golba KS, Prior DL, Rouleau JL, Bonow RO. Navigating the crossroads of coronary artery disease and heart failure. Circulation 2006:114:1202-1213
34. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med 2006;119:S3-S10.
35. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC; OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure.JAMA. 2006;296:2217-2226.
36. Gheorghiade M, Shin DD, Thomas TO, Brandimarte F, Fonarow GC, Abraham WT. Congestion is an important diagnostic and therapeutic target in heart failure. Rev Cardiovasc Med. 2006;7 Suppl 1:S12-24.
37. Gheorghiade M. The clinical effects of vasopressin receptor antagonists in heart failure. Cleve Clin J Med. 2006;73 :S24-S29;
38. Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation. 2006;113:2556-2564.
39. Gheorghiade M, Gottlieb SS, Udelson JE, Konstam MA, Czerwiec F, Ouyang J, Orlandi C; Tolvaptan Investigators. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia.Am J Cardiol. 2006;97:1064-1067.
40. Goldberger J, Subacius H, Schaechter A, Howard A , Berger R, Shalaby A, Levine J, Kadish A, for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators: Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 2006;48:1228-1233.
41. Goldberger J: Unraveling the mysteries of the AV node. Heart Rhythm 2006;3:1001-1002.
42. Goldberger J: Atrial fibrillation ablation: location, location, location. J Cardiovasc Electrophysiol 2006;17:1271.
43. Goldberger JJ, Le FK, Lahiri M, Kannankeril PJ, Ng J, Kadish AH: Assessment of parasympathetic reactivation after exercise. Am J Physiol 2006;90:H2446-H2452.
44. Goldschmidt-Clermont PJ, Creager MA, Losordo DW, Lam GK, Wassef M, Dzau VJ: Atherosclerosis 2005: recent discoveries and novel hypotheses. Circulation 2005;112:3348-3353; 2006;113:e681.
45. Hamada H, Kishimoto S, Losordo DW: Topical sonic hedgehog gene therapy accelerates wound healing in diabetes by enhancing endothelial progenitor cell mediated microvascular remodeling. Circulation. 2006;113:2413-2424.
46. Hamada H, Kim MK, Iwakura A, Ii M, Thorne T, Qin G, Asai J, Tsutsumi Y, Sekiguchi H, Silver M, Wecker A, Bord E, Zhu Y, Kishore R, Losordo DW. Estrogen receptors alpha and beta mediate contribution of bone marrow-derived endothelial progenitor cells to functional recovery after myocardial infarction. Circulation 2006;114:2261-2270.
47. Harinstein ME, Gheorghiade M. Acute heart failure syndromes: highlights from the ESC Working Group on Acute Cardiac Care Meeting Prague, Czech Republic 2006. Acute Card Care 2006;8:179-180.
48. Ii M, Losordo DW: Statins and the endothelium. Vascul Pharmacol. 2006;46:1-9
49. Ii M, Takenaka H, Asai J, Ibusuki K, Mizukami Y, Maruyama K, Yoon Y-S, Wecker A, Luedemann C, Eaton E, Thorne T, Losordo DW: Endothelial progenitor thrombospondin-1 mediates diabetes induced delay in reendothelialization following arterial injury. Circ Res 2006:98:697-704.
50. Iwakura A, Shastry S, Luedemann C, Kawamoto A, Masuda H, Asahara T, Losordo DW: Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia induced neovascularization via eNOS mediated activation of MMP-9. Circulation 2006:113:1605-1614.
51. Januzzi JL, Sakhuja R, O’Donoghue M, Baggish L, Anwaruddin S, Chae CU, Cameron R, Krauser DG, Tung R, Camargo CA, Lloyd-Jones DM. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of one-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 2006; 166: 315-320.
52. Johnson ML, Rajamannan N. Diseases of Wnt signaling. Rev Endocr Metab Disord 2006;7:41-49.
53. Kadish A, Schaechter A, Subacius H, Thattassery E, Sanders W, Anderson KP, Dyer A, Goldberger J, Levine J. Patients with recently diagnosed nonischemic cardiomyopathy benefit from implantable cardioverter-defibrillators. J Am Coll Cardiol. 2006;47:2477-2482.
54. Kawamoto A, Kusano K, Murayama T, Iwasaki H, Oyamada A, Silver M, Hulbert C, Gavin M, Hanley A, Ma H, Kearney M, Asahara T, Losordo DW: CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. Circulation 2006;114:2163-2169.
55. Kean AJ, McCloskey, V, Seghatol FF, Ewert GD, Mehlman DJ, McPherson DD, Rigolin VH. Preservation of left ventricular systolic and diastolic function in amateur athletes following completion of a marathon. J Am Soc Echocardiogr 2006:19;202-205.
56. Klein L, O’Connell JB. Prognostic factors in patients hospitalized with acute heart failure syndrome. J Geriatric Cardiol 2006;3:199-209.
57. Klocke FJ, Wu E, Lee DC, “Shades of Gray” in cardiac magnetic resonance imaging of infarcted myocardium: can they tell us what they want us to? Circulation 2006; 114:8-10.
58. Koktzoglou I, Harris KR, Tang R, Kane BJ, Misselwitz B, Weinmann HJ,. Lu B,. Nagaraj A,. Roth SI,. Carroll TJ,. McPherson DD,. Li D. Gadofluorine-enhanced magnetic resonance imaging of carotid atherosclerosis in Yucatan miniswine. Invest Radiology. 41:299-304.
59. Lameire N, Adam A, Becker CR, Davidson CJ, McCullough PA, Stacul F, Tumlin J. Baseline renal function screening. Am J Cardiol 2006;98(suppl):21K-26K.
60. Lee DC, Klocke FJ. Magnetic resonance approaches and recent advances in myocardial perfusion imaging. Curr Cardiol Rep 2006;8:59-64.
61. Lee J, Wecker A, Losordo DW, Yoon YS: Derivation and characterization of bone marrow-derived multipotent stem cells. Exp Hematol 2006;34:1602-1603.
62. Lloyd-Jones DM, Leip EP, Larson MG, D’Agostino RB, Beiser A, Wilson PWF, Wolf PA, Levy D. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006; 113: 791-798.
63. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative Review: Assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med 2006; 145: 35-42.
64. Lloyd-Jones DM, Tian L. Predicting cardiovascular risk: so what do we do now? Editorial. Arch Intern Med 2006; 166: 1342-1344.
65. Lloyd-Jones DM. Short-term versus long-term risk for coronary artery disease: Implications for lipid guidelines. Curr Opin Lipidology 2006; 17: 619-625.
66. Lloyd-Jones DM. Lifetime risk for atrial fibrillation. Cardiology Review 2006; 23: 35-40.
67. McCullough PA, Adam A, Becker CR, Davidson CJ, Lameire N, Stacul F, Tumlin J. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006;98(suppl):5K-13K.
68. McCullough PA, Adam A, Becker CR, Davidson CJ, Lameire N, Stacul F, Tumlin J. Risk Prediction of Contrast-Induced Nephropathy. Am J Cardiol 2006;98(suppl):27K- 36K.
69. Mehta RH, Roe Mt, Chen Ay, Lytle BL, Pollack CV Jr, Brindis RG, Smith SC Jr, Harrington RA, Fintel DJ, Fraulo ES, Califf RM, Gibler WB, Ohman Em, Peterson ED. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med 2006;166:2027-2034.
70. Mehrotra P, Choi JW, Flaherty J, Davidson CJ. Percutaneous coronary intervention in a patient with cardiac dextroversion. Baylor Univ Med Center Proc 2006;19:226.
71. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, McKoy JM, Davidson CJ, Raisch DW, Belknap SM, Gligoric G, West DP, Yarnold PR, Gage JE, Morse RE, Davidson L, Feldman MD. Hypersensitivity cases associated with drug-eluting coronary stents: A review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175-181.
72. Ng J, Kadish AH, Goldberger JJ: Effect of electrogram characteristics on the relationship of dominant frequency to atrial activation rate in atrial fibrillation. Heart Rhythm 2006;3:1295-1305.
73. Ortiz, J, Shin D, Rajamannan NM. Management of bicuspid of aortic valve disease. Curr Treat Options Cardiovasc Med 2006;8:461-467.
74. Payvar S, Orlandi C, Stough WG, Elkayam U, Ouyang J, Casscells SW, Gheorghiade M; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Comparison of 60-day mortality in hospitalized heart failure patients with versus without hypothermia.Am J Cardiol 2006;98:1485-1488.
75. Pitt B, Ferrari R, Gheorghiade M, van Veldhuisen DJ, Krum H, McMurray J, Lopez-Sendon J. Aldosterone blockade in post-acute myocardial infarction heart failure.Clin Cardiol. 2006;29:434-438.
76. Pitt B, Fonarow GC, Gheorghiade M, Deedwania PC, Duprez DA. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade. Am J Cardiol. 2006;97:26F-33F.
77. Pitt B, Gheorghiade M, Zannad F, Anderson JL, van Veldhuisen DJ, Parkhomenko A, Corbalan R, Klug EQ, Mukherjee R, Solomon H; On behalf of the EPHESUS Investigators. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%. Eur J Heart Fail. 2006;8:295-301.
78. Persell SD, Lloyd-Jones DM, Baker DW. Implications of changing National Cholesterol Education Program guidelines for the treatment and control of hypercholesterolemia in the United States. J Gen Intern Med 2006; 21: 171-176.
79. Persell SD, Lloyd-Jones DM, Baker DW. National Cholesterol Education Program risk assessment and potential for risk misclassification. Prev Med 2006; 43: 368-371.
80. Qin G, Ii M, Silver M, Wecker A, Bord E, Ma H, Gavin M, Goukassian DA, Yoon YS, Papayannopoulou T, Asahara T, Kearney M, Thorne T, Curry C, Eaton L, Heyd L, Dinesh D, Kishore R, Zhu Y, Losordo DW: Functional disruption of 4 integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization. J Exp Med. 2006 203:153-63.
81. Qin G, Kishore R, Dolan CM, Silver Ml, Wecker A, Luedemann CN, Thorne T, Hanley A, Curry C, Heyd L, Dinesh D, Kearney M, Martelli F, Murayama T, Goukassian DA, Zhu Y, Losordo DW: Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF. Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11015-11020.
82. Rashba EJ, Estes NAM, Wang P, Schaechter A, Howard A, Zareba W, Couderc JP, Perkiomaki J, Levine J, Kadish A, DEFINITE Investigators. Preserved heart rate variability identifies low-risk patients with nonischemic dilated cardiomyopathy: results from the DEFINITE trial. Heart Rhythm 2006;3:281-286.
83. Rajamannan NM, Subramaniam M, Abrahams T, Vasile V, Monroe D, Ackerman M, Ackerman, Teng, L, Spelsberg, T, TGFb inducible early gene-1 (TIEG1) and hypertrophic cardiomyopathy: discovery and characterization of a novel signaling pathway. J Cell Biochem 2006;100:315-325.
84. Rajamannan, NM, Calcific aortic stenosis: a disease ready for prime time. Circulation 2006;114:2007-2009.
85. Rigolin, VH. Echocardiography in wmen. J Am Soc Echocardiogr. 2006;19:A21-2.
86. Rajasingh J, Bord E, Luedemann C, Asai J, Hamada H, Thorne T, Qin G, Goukassian D, Zhu Y, Losordo DW, Kishore R. IL-10-induced TNF-alpha mRNA destabilization is mediated via IL-10 suppression of p38 MAP kinase activation and inhibition of HuR expression. FASEB J. 2006;20:2112-2114
87. Rangasetty UC, Gheorghiade M, Uretsky BF, Orlandi C, Barbagelata A. Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure. Expert Opin Investig Drugs. 2006;15:533-540.
88. Robin J, Weinberg K, Tiongson J, Carnethon M, Reddy M, Ciaccio C, Quadrini M, Hsu J, Fan J, Choi P, Kadish A, Goldberger J, Passman R: Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter-defibrillator recipients. Heart Rhythm 2006;3:1196-1201.
89. Robinson JG, Stone NJ. Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am J Cardiol 2006;98:1405-1408.
90. Robinson JG, Stone NJ. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol 2006;98:39i-49i.
91. Rosenson RS. Field of confusion: future prospects for fibrate therapy in cardiovascular disease. Curr Atheroscler Rep. 2006;8:219-222,
92. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis. 2006;185:327-330
93. Rosenson RS. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. Am Heart J 2006;151:556-563
94. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.N Engl J Med. 2006;355:2099-2112.
95. Schweiger MJ, Chambers CE, Davidson CJ, Zhang S, Blankenship J, Bhalla NP, Block PC, Dervan JP, Gasperetti C, Gerber L, Kleiman NS, Krone RJ, Phillips WJ, Seigel RM, Uretsky BF, Laskey WK. Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures. Cath Cardiovas Intervent 2007;69:135-140.
96. Shors SM, Cotts WG, Pavlovic-Surjancev B, Gheorghiade M, Carr JC, McCarthy PM, Pereles SF, Finn PJ. Non-invasive cardiac evaluation in heart failure patients using magnetic resonance imaging: a feasibility study. Heart Fail Rev. 2006;10:265-273.
97. Shintani S, Kusano K, Ii M, Iwakura A, Heyd L, Curry C, Wecker A, Gavin M, Ma H, Kearney M, Silver M, Thorne T, Murohara T, Losordo DW: Synergistic effect of combined intramyocardial CD34+ cells and VEGF2 gene therapy after MI. Nature Clinical Practice in Cardiovascular Medicine 2006:Suppl 1:S123-128.
98. Sibley C, Stone NJ. Familial hypercholesterolemia: a challenge of diagnosis and therapy. Cleve Clin J Med 2006;73:57-64.
99. Sinha S, Poh KK, Sodano D, Flanagan J, Ouilette C, Kearney M, Heyd L, Wollins J, Losordo DW, Weinstein R: Safety and efficacy of peripheral blood progenitor cell mobilization and collection in patients with advanced coronary heart disease. J Clin Apheresis 2006;21:116-120.
100. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Grundy SM, Hiratzka L, Jones D, Krumholz HA, Moca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC secondary prevention for patients with coronary and other vascular disease: 2006 update. Circulation 2006:113;2363-2372 and J Am Coll Cardiol 2006;47:2130-2139
101. Stacul F, Adam A, Becker CR, Davidson CJ, Lameire N, McCullough PA, Tumlin J. Strategies to reduce risk of contrast-induced nephropathy. Am J Cardiol 2006;98(suppl): 59K-77K.
102. Stone NJ. Successfulcontrol of dyslipidemia in patients with metabolic syndrome: focus on lifestyle changes. Clin Cornerstone 2006;8 Suppl 1:S15-20.
103. Stone NJ. Therapy and clinical trials. Curr Opin Lipidol 2006;17:199-201.
104. Stone NJ. Clinicalconfidence and the three C's: caring, communicating, and competence. Am J Med 2006;119:1-2.
105. Strickberger SA, Benson DW, Biaggioni I, Callans DJ, Cohen MI, Ellenbogen KA, Epstein AE, Friedman P, Goldberger J, Heidenreich PA, Klein GJ, Knight BP, Morillo CA, Myerburg RJ, Sila CA: AHA/ACCF Scientific Statement on the Evaluation of Syncope. Circulation 2006;113;316-327 and J Am Coll Cardiol 2006;47:473-484.
106. Terblanche M, Almog Y, Rosenson RS, Smith TS. Hackam DG. Statins: panacea for sepsis?. Lancet Infect Dis. 2006;6:242-248,
107. Thom T, Haase N, Rosamond R, Howard VJ, Rumsfeld J, Manolio T, Zheng Z, Flegal K, O’Donnell C, Kittner S, Lloyd-Jones D, Goff D, Hong Y. Heart Disease and Stroke Statistics — 2006 Update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85-e151.
108. Thompson PD, Clarkson PM, Rosenson RS. The National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am J Cardiol. 2006;97:69C-76C
109. Tiongson J, Robin J, Chana A, Shin DD, Gheorghiade M. Are the American College of Cardiology/Emergency Cardiac Care (ACC/ECC) guidelines useful in triaging patients to telemetry units? Acute Card Care. 2006;8:155-60.
110. Tiukinhoy-Laing SD, Rossi JS, Bayram M, De Luca L, Gafoor S, Blei A, Flamm S, Davidson CJ, Gheorghiade M. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol. 2006;98:178-181.
111. Tricoci P, Roe MT, Mulgund J, Newby LK, Smith SC Jr, Pollack CV Jr, Fintel, DJ, Cannon CP, Bhatt DL, Gibler WB, Ohman EM, Peterson ED, Harrington RA. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med 2006;166:806-811
112. Tumlin J, Stacul F, Adam A, Becker CR, Davidson CJ, Lameire N, McCullough PA. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 2006;98(suppl):4K-20K.
113. Welt FG, Losordo DW: Cell therapy for acute myocardial infarction: curb your enthusiasm? Circulation 2006:113:1272-1274.
114. Wilson BD, Ii M, Park KW, Suli A, Sorensen LK, Larrieu-Lahargue F, Urness LD, Suh W, Asai J, Kock GA, Thorne T, Silver M, Thomas KR, Chien CB, Losordo DW, Li DY. Netrins promote developmental and therapeutic angiogenesis. Science. 2006;313(5787):640-644.
115. Yang CW. Carr JC. Francois CJ. Shea SM. Deshpande VS. Meyers SN. Beohar N. Finn JP. Li D. Coronary magnetic resonance angiography using magnetization-prepared contrast-enhanced breath-hold volume-targeted imaging (MPCE-VCATS). Invest Radiol. 2006;41:639-644.
116. Zannad F, Adamopoulos C, Mebazaa A, Gheorghiade M. The challenge of acute decompensated heart failure. Heart Fail Rev. 2006;11:135-139.
1. Abraham W, Greenberg B, Fonarow G, Albert N, Chiswell K, Stough W, Gheorghiade M, O’Connor C, Sun J, Yancy C, Young J. Cardiac resynchronization device placement during hospitalization for heart failure in associated with a significant improvement in early clinical outcomes. J Am Coll Cardiol 2006;47:19A
2. Adams Jr. KF, Patterson JH, Stough WG, Alla F, O’Connor CM, Lee CR, Schwartz TA, Gheorghiade M. Relationship of clinical signs and chest X-ray congestion to the efficacy of digoxin in patients with chronic heart failure: a retrospective analysis of the Digoxin Investigation Group Trial. J Card Failure 2006;12:S87.
3. Albert N, Fonarow G, Abraham W, Chiswell K, Stough W, Gheorghiade M, Greenberg B, O’Connor C, Yancy C, Young J. Do hospitals that provide heart failure patient education prior to discharge also promote continuity of care? A report from OPTIMIZE HF. J Am Coll Cardiol 2006;47:267A
4. Ardehali H, Jones S, Marben E. Multiprotein complex contains proteins of the mitochondrial permeability transition pore and the mitochondrial ATP-sensitive K+ channel. Circ Res 2006;99:E40.
5. Arora R, Dibs S, Passman R, Taneja T, Rudin A, Goldberger JJ, Kadish AH: Endocardial ablation of atrial tachycardias occurring after epicardial maze procedures. Heart Rhythm 2006;3:S278
6. Arora R, Ng J, Mylonas I, Ulphani JS, Gordon D, Morris A, Goldberger JJ, Kadish AH: Activation profile of the pulmonary veins in response to autonomic maneuvers. Heart Rhythm 2006;3:S308
7. Baggish AL, Lloyd-Jones DM, O’Donoghue M, Sakhuja R, Lainchbury JG, Richards AM, Januzzi JL. A validated clinical and biochemical risk score for prediction of one-year mortality in dyspneic Emergency Department patients: The ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Mortality Risk Score. Circulation 2006; 114: II-529.
8. Bahrami H, Bluemke DA, Kronmal R, Bertoni AG, Lloyd-Jones DM, Shahar E, Szklo M, Lima JAC. Novel metabolic risk factors for incident heart failure and their relationship with obesity in The Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2006; 114: II-870.
9. Beohar N, Goodreau L, Kip K, .Ricciardi M, Benzuly K, Meyers S, Orlick A, Williams DO, Bennett C, Davidson CJ. Off-label and untested use of drug eluting stents: six month outcomes from the DEScover Registry. Circulation 2006;114:II-686
10. Beohar N, Davidson CJ, Hillegass W, Massaro E, Hlatky M, Krauland M, Korytkowski M, Melsop K, Brooks M. Impact of asyomatic and symptomatic end organ effects of diabetes mellitus on the quality of life in the Bypass Angioplasty Revascularization Investigation of Type 2 Diabetes (BARI 2D). Circulation 2006;114:845.
11. Beohar N, Goodreau L, Kip K, .Ricciardi M, Benzuly K, Meyers S, Orlick A, Williams DO, Bennett C, Davidson CJ. Off-Label and Untested Use of Drug Eluting Stents: Six Month Outcomes from the DEScover Registry. Am J Cardiol 2006,98:2M.
12. Berry JD, Greenland P, Lloyd-Jones DM. Traditional risk factors and major ECG abnormalities for both short-term and long-term follow-up. Circulation 2006; 114: II-882.
13. Bowers M, Naik T, Ardehali H. 2006 A-calcitonin gene-related peptide (a-CGRP) protects myocardial cells against oxidative stress through a mitochondrial-dependent pathway. Circulation 2006;114:1122.
14. Cavanaugh MW, Lloyd-Jones DM. Systematic examination of risk factor levels associated with high and intermediate 10-Year risks for coronary heart disease in the ATP-III risk assessment tool. Circulation 2006; 114: II-868.
15. Chae CU, Lloyd-Jones DM, Dec GW, Stevenson LW, Ridker PM, Januzzi JL. C-reactive protein predicts mortality in patients with acute heart failure. Circulation 2006; 113: e336.
16. Cowart D, Amato A, Zhang D, Valentini G, Carminati P, Adamson PB, Gheorghiade M, Brass E. The use of non-invasive impedence cardiography (ICG) to define the active dose range for invasive right heart hemodynamic studies: the istaroxime experience. J Card Failure 2006;12:S78.
17. Decker R, Nakamura S, Naik T, Ardehali H. 2006 b adrenergic phosphorylation of contractile proteins in cultured neonatal rat ventricular myocytes. Circulation 2006;114:1115.
18. Dibs S, Hsu J, Cohoon K, Wu G, Sincleair T, Pereles S, Carr J, Subacius H, Kadish A, Goldberger J: Effects of catheter ablation for atrial fibrillation on left and right atrial volume and function. J Am Coll Cardiol 2006;47:18A.
19. Dibs S, Ng J, Ulphani J, Arora R, Passman R, Kadish A, Goldberger J: Regularity and centrifugal dissipation of frequency: evidence that high-frequency sites are drivers in persistent atrial fibrillation. Circulation 2006;114:II-519.
20. Fonarow G, Abraham W, Albert N, Stough W, Gheorghiade M, Greenberg B, O’Connor C, Sun J, Yancy C, Young J. Carvedilol use at discahrge in patients hospitalized for heart failure is associated with markedly improved survival. J Am Coll Cardiol 2006;47:53A
21. Fonarow G, Abraham W, Albert N, Chiswell K, Stough W, Gheorghiade M, Greenberg B, O’Connor C, Sun J, Yancy C, Young J. ACC/AHA performance measures for patients hospitalized with HF: are they predictive of clinical outcomes. J Am Coll Cardiol 2006;47:255A
22. Gordon L, Prachand S, Singh A, Ardehali H. 2006. Herceptin, an antibody against erbB2 receptor, induces cardiomyocyte death by increasing production of reactive oxygen species. Circulation 2006;114:1611.
23. Hillis MB, Everatt G, Subacius H, Kadish AH, Schaechter A, Pavri BB. Planar QRS-T Angle predicts events in patients with non-ischemic cardiomyopathy: an analysis of the DEFINITE database. Heart Rhythm 2006.3:P2-65.
24. Januzzi JL, Chae CU, Baggish AL, Lee-Lewandrowski E, Sluss P, Lewnadrowski KB, Lloyd-Jones DM. C-reactive protein concentrations at emergency department presentation strongly predict one year mortality in dyspneic patients. J Amer Coll Cardiol 2006; 47 (4 suppl A): 67A.
25. Kansal P, Ortiz JT, Bucciarelli-Ducci C, Lee DC, Holly TA, Klocke FJ, Bonow RO, Wu E. Infarct size by contrast-enhanced magnetic resonance imaging predicts cardiovascular outcomes after acute myocardial infarction. J Cardiovasc Magnetic Res 2006;8:109.
26. Kim B, Davidson CJ, Kwaan HC, Zakarija A, Bandarenko N, Pandey DK, Sarode R, McKoy JM, Tevar AD, Cursio JF, Raife TJ, Kiss JE, Raisch DW, Sadler JE, Ortel TL, Zheng XL, Kato S, Matsumoto M, Uemura M, Fujimura Y, Bennett CL. Characteristics of two thrombotic thrombo-cytopenic purpura (TTP) syndromes associated with ticlopidine and clopidogrel: results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Research Group. Circulation 2006;114:II-72.
27. Klein L, Massie BM, Leimberger JD, O’Connor CM, Piña IL, Adams KF Jr, Califf RM, Gheorghiade M. Changes in renal function during hospitalization for worsening heart failure predict post-discharge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME - CHF). J Am Coll Cardiol 2006;47(Suppl. 1):87A.
28. Lahiri M, Ng J, Kadish A, Goldberger J: Changes in parasympathetic tone result in QT-RR interval hysteresis during exercise and recovery. J Am Coll Cardiol 2006;47:13A, 2006.
29. Lahiri MK, Ng J, Kadish AH, Goldberger JJ: Post-exercise recovery of autonomic tone, heart rate and QT interval: implications for risk of sudden death. Heart Rhythm 2006;3:S313
30. Lloyd-Jones DM. Predicting lifetime risk for cardiovascular disease based on risk factor burden. Atherosclerosis 2006; 7(Supplement): 483.
31. Moura LM, Ramos SF, Zamorano JI, Azevedo LF, Rocha-Gonzalves F, Rajamannan NM. Rosuvastatin Affecting Aortic Valve Endothelium (RAAVE) to slow progression of aortic stenosis. Circulation 2006;114:II-175.
32. Ng J, Arora R, Ulphani JS, Shade G, Gordon D, Goldberger JJ, Kadish AH: The effect of sympathovagal interactions on dominant frequency changes of the pulmonary veins and left atrium during atrial fibrillation. Heart Rhythm 2006;3:S223.
33. O’Connor C, Abraham W, Albert N, Clare R, Stough W, Gheorghiade M, Greenberg B, Yancy C, Young J, Fonarow G. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure. J Am Coll Cardiol 2006;47:83A
34. Ortiz JT, Kansal P, Tejedor P, Bucciarelli-Ducci C, Holly TA, Carr JC, Klocke FJ, Bonow RO, Wu E. Assessment of diastolic dysfunction after myocardial infarction using phase-contrast magnetic resonance imaging. J Cardiovasc Magnetic Res 2006;8:60.
35. Ortiz JT, Kansal P, Tejedor P, Bucciarelli-Ducci C, Lee DC, Holly TA, Carr JC, Klocke FJ, Bonow RO, Wu E. Progressive infarct healing and left ventricular remodeling 4 months and more than 1 year following an acute myocardial infarction.“ J Cardiovasc Magnetic Res 2006;8:149.
36. Ortiz JT, Meyers SN, Davidson CJ, Lee DC, Kansal P, Klocke FJ, Holly TA, Bonow RO, Wu E. Impact of residual flow on the reduction in infarct transmurality and preservation of myocardial salvage following reperfused ST-segment elevation myocardial infarction. Circulation 2006;114:II-343
37. Ortiz JT, Meyers, SN, Davidson CJ, Holly TA, Klocke FJ, Bonow RO, Wu E. Collateral flow and early reperfusion reduce infarct transmurality and prevent left ventricular remodeling after ST segment elevation acute myocardial infarction. Circulation 2006;114:II-344
38. Racker DK, Schlessinger S, Li X, Kadish AH. The atrioaortic, atrioventricular and ventriculoaortic septae in the human heart. FASEB J 2006;20:A323.
39. Racker DK, Li X, Schlesinger S, Kadish AH. Atrial myocardium and the atrionodal bundles demonstrate distinct plateau action potentials. FASEB J 2006;20:A323
40. Rajamannan NM, Subramaniam, M, Caira, F. Stock S R, Hefferan, R, Flores A, Spelsberg, TC, Atorvastatin attenuates experimental hypercholesterolemia induced aortic valve calcification and osteoporosis via paradoxical regulation of Cbfa1.Circulation 2006;114:II-111.
41. Rubenstein J, Goldberger J, Ortiz JT, Kadish A, Passman R, Bonow RO, Wu E. The use of contrast-enhanced cardiac magnetic resonance imaging after acute myocardial infarction for prediction of future ventricular dysfunction and ICD implantation qualification. Circulation 2006;114:II-407
42. Russo RJ, Wong SC, Marchant D, Attubato MJ, Korr K, Davidson CJ, Tuzcu EM,Feldman T, Ling FS, Silva PD. Is left main angiographic lesion location predictive of a significant stenosis by intravascular ultrasound and the need for revascularization? Observations from the Left Main IVUS Registry. Circulation 2006;114:II-508.
43. Schrier R, Gheorghiade M, Verbalis J, Berl T, Gross P, Czerwiec F, Oralndi C ; for the SALT Trial Investigators. Results from the SALT 1 and 2 Trials : Multicenter, randomized, placebo-controlled trials in patients with euvolemic and hypervolemic hyponatremia. Circulation 2006;114:II-570.
44. Shin DD, Caira FC, Machepalli P, Rafael M, Flores A, Rajamannan NM. Atorvastatin attenuates Notch1/Lrp5 induced osteoblast expression in bicuspid stenotic aortic valves. Circulation 2006;114: II-792.
45. Singh PP, Abbott JD, Lombardro MS, Sutton-Tyrell K, Massaro E, Woodhead GA, Krauland MG, Rutter MK, Tsapatsaris NP, Beohar N, Piemonte TC, Nesto RW. Prevalence and clinical characteristics of peripheral arterial disease in patients with Type 2 diabetes and CAD enrolled in the BARI 2D Trial. Circulation 2006;114:II-379
46. Stough W, Fonarow G, Abraham W, Albert N, Gheorghiade M, Greensberg B, O’Connor C, Sun J, Yancy C, Young J. Characteristics, treatments and outcomes of patients hospitalized for heart failure with preserved sysytolic function: a report from OPTIMIZE HF. Present at the American College of Cardiology Scientific Session. Atlanta, Georgia. March 13, 2006. J Am Coll Cardiol 2006;47, A
47. Stough W, Fonarow G, Albert N, Abraham W, Lokhnygina Y, Gheorghiade M, Greenberg B, O’Connor C, Yancy C, Young J. Comparison of factors identified as precipitating heart failure hospital admissions and clincal outcomes: a report from OPTIMIZE HF. J Am Coll Cardiol 2006;47:262A
48. Sun L, Shukair S, Moazed F, Naik T, Machepalli P, Ardehali H. 2006. Mitochondrial binding and glucose phosphorylation are both needed for the protective effects of hexokinase I and II. Circulation 2006;114:1291.
49. Sun L, Shukair S, Moazed F, Naik T, Ardehali H 2006 Hexokinase I and II protect against oxidant-induced cell death by increasing glucose phosphorylation and inhibition of mitochondrial permeability transition. Circ Res 2006;99:E24
50. Ulphani J, Cain JH, Arora R, Gordon D, Shen S, Goldberger JJ, Kadish AH: Role of the ligament of marshall in vagal control of the posterior left atrium. Heart Rhythm 2006;3:S224
51. Wu E, Ortiz JT, Kansal P, Lee DC, Klocke FJ, Carr JC, Holly TA, Bonow RO. Infarct mass by contrast-enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index. Circulation 2006;114:II-461
